Labcorp, Thermo Fisher and Charles River lead fragmented omics lab services market

By AI, Created 5:33 PM UTC, May 18, 2026, /AGP/ – Labcorp Holding, Thermo Fisher Scientific and Charles River Laboratories are among the top competitors in the global omics lab services market, which remains highly fragmented. The Business Research Company says the top 10 players held just 6% of revenue in 2024, underscoring room for consolidation, partnerships and technical differentiation.

Why it matters: - The omics lab services market is still wide open, with no dominant player controlling a large share of revenue. - That fragmentation creates room for service providers to win business through better sequencing, multi-omics analysis, bioinformatics and data interpretation. - Demand is being shaped by precision medicine, high-throughput testing and the need for reproducible research data.

What happened: - The Business Research Company identified the leading competitors in the global omics lab services market in its Omics Lab Services Global Market Report 2026. - Labcorp Holding Inc., including Covance, led global sales in 2024 with a 1% market share. - Thermo Fisher Scientific Inc. (PPD), Charles River Laboratories and Eurofins Scientific SE each held 1% market share. - BGI Genomics Co. Ltd. held 0.4%. - Novogene Co. Ltd. held 0.2%. - GENEWIZ from Azenta, Frontage Laboratories, Somalogic Inc. (SomaScan®) and Metabolon Inc. each held 0.1% or less.

The details: - The top 10 players accounted for 6% of total market revenue in 2024. - The market includes a long list of global life sciences, genomics, proteomics and bioinformatics providers. - Major companies named in the report include Labcorp Holding, Thermo Fisher Scientific, Charles River Laboratories, Eurofins Scientific, BGI Genomics, Novogene, GENEWIZ from Azenta, Frontage Laboratories, Somalogic, Metabolon, Centogene, ProtaGene, Revvity, Psomagen, Biocrates Life Sciences, Edinburgh Genomics, Source BioScience, Fios Genomics, Creative Proteomics, Biognosys, OmicScouts, Sciomics, PreOmics, Proteome Sciences, Lipotype Lipidomics, Panome Bio and ATLAS Biolabs. - The report says competitive positioning depends on advanced next-generation sequencing, high-throughput multi-omics analysis, cloud-based bioinformatics platforms and integrated data interpretation. - The report also points to precision medicine applications, data accuracy and computational biology integration as core differentiators. - Major raw material suppliers include Illumina, Thermo Fisher Scientific, Agilent Technologies, QIAGEN, Bruker, Waters, Bio-Rad Laboratories, Roche, Danaher, Oxford Nanopore, Pacific Biosciences, Sartorius, Merck KGaA, Charles River Laboratories International, Eurofins Scientific, Abcam, Bio-Techne, GenScript, Takara Bio, Hamilton, Revvity, Standard BioTools and 10x Genomics. - Major wholesalers and distributors include Avantor, Fisher Scientific International, VWR International, McKesson, Cardinal Health, Medline, Owens & Minor, Henry Schein, Midland Scientific and Scil Animal Care Company. - Major end users include Roche Diagnostics, Illumina Clinical Services, Quest Diagnostics, Laboratory Corporation of America Holdings, 23andMe, AncestryDNA and Genentech. - The report includes a sample request link: Request a free sample. - The full report is available here: Access the detailed report.

Between the lines: - The low market concentration suggests competition is driven more by technical capability and partnerships than by scale alone. - Entry barriers remain meaningful because omics services require strict data quality, regulatory compliance and complex multi-omics integration. - The report frames AI-driven bioinformatics and integrated platforms as a key way companies are trying to improve automation, accuracy and scalability.

What’s next: - The report expects strategic collaborations, service innovation and regional expansion to strengthen the position of leading companies. - Growth in advanced precision medicine, biological testing and integrated bioinformatics platforms is likely to keep pressure on providers to upgrade infrastructure and analytics. - The report highlights high-throughput genomics platforms as a major competitive trend, including a September 2024 launch by the Translational Genomics Research Institute of its Center for Spatial Multi-Omics, or COSMO, offering sequencing-based Visium HD and tissue microarray services.

The bottom line: - The omics lab services market is fragmented, technically demanding and still up for grabs for providers that can pair lab scale with strong analytics and reproducibility.